| CTRI Number |
CTRI/2025/10/096197 [Registered on: 21/10/2025] Trial Registered Prospectively |
| Last Modified On: |
17/10/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Other |
|
Public Title of Study
|
Estimate the predictive role of serum SIRT-1 level and genetic association of PCSK9 gene with metabolic syndrome in patients of coronary artery disease |
|
Scientific Title of Study
|
Association of serum SIRT-1 level and PCSK9 gene polymorphism in coronary artery disease with metabolic syndrome |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Anwar Pervez |
| Designation |
post graduate resident |
| Affiliation |
Maulana Azad Medical college |
| Address |
department of Biochemistry
Maulana Azad medical college
Bahadur Shah Zafar Marg
Delhi
Central DELHI 110002 India |
| Phone |
9634608046 |
| Fax |
|
| Email |
biochemdranwar@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Lal Chandra |
| Designation |
Director Professor |
| Affiliation |
Maulana Azad medical college |
| Address |
department of Biochemistry
Maulana Azad medical college
Bahadur Shah Zafar Marg
Delhi
Central DELHI 110002 India |
| Phone |
9873167313 |
| Fax |
|
| Email |
drlchandra70@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Lal Chandra |
| Designation |
Director Professor |
| Affiliation |
Maulana Azad medical college |
| Address |
department of Biochemistry
Maulana Azad medical college
Bahadur Shah Zafar Marg
Delhi
DELHI 110002 India |
| Phone |
9873167313 |
| Fax |
|
| Email |
drlchandra70@gmail.com |
|
|
Source of Monetary or Material Support
|
| Maulana Azad Medical college,
Delhi university,
Government of NCT of Delhi |
|
|
Primary Sponsor
|
| Name |
Maulana Azad Medical college |
| Address |
Bahadur Shah Zafar marg
New Delhi 110002 |
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Anwar Pervez |
Maulana Azad Medical college |
Bahadur Shah Zafar marg
New Delhi 110002 Central DELHI |
9634608046
biochemdranwar@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| INSTITUTIONAL ETHICS COMMITTEE |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: I259||Chronic ischemic heart disease, unspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
40.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
Cases of stable and unstable angina, and follow cases of myocardial infarction |
|
| ExclusionCriteria |
| Details |
All other cardiac disorders |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| association of serum SIRT1 and metabolic syndrome in patients of coronary artery disease |
4 weeks |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| association between pcsk9 gene polymorphism & serum SIRT1 in patients of coronary artery disease with metabolic syndrome |
4 weeks |
|
|
Target Sample Size
|
Total Sample Size="60" Sample Size from India="60"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
10/10/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices).
- What additional supporting information will be shared?
Response - Clinical Study Report
- Who will be able to view these files?
Response - Researchers who provide a methodologically sound proposal.
- For what types of analyses will this data be available?
Response - To achieve aims in the approved proposal.
- By what mechanism will data be made available?
Response - Proposals should be directed to [biochemdranwar@gmail.com].
- For how long will this data be available start date provided 01-01-2027 and end date provided 31-12-2031?
Response - Immediately following publication. No end date.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
|
Brief Summary
|
The present study will be conducted with the primary objective of discovering association of serum SIRT1 and PCSK9 gene polymorphism with metabolic syndrome in patients of coronary artery disease The subjects(60) will be the diagnosed cases of coronary artery disease and divided into two groups one with metabolic syndrome and the other without metabolic syndrome based on the National Cholestrol Education Program Adult Treatment Panel III definition After informed consent 5 ml of venous blood sample will be collected in the plain vial 3ml and EDTA vial 2ml Serum SIRT1 level will be estimated by ELISA technique following the protocol as per manual The genotyping for PCSK9 gene polymorphism will be done using Allele Specific Oligonucleotide Polymerase chain reaction ASO PCR and RFLP
|